摘要
目的研究和评价奥拉西坦治疗儿童脑性瘫痪的临床疗效和安全性。方法对60例儿童脑性瘫痪患者进行随机双盲实验阳性药物吡拉西坦为对照,实验组采用奥托西坦。采用韦氏学前及入学儿童智能量表(WPPSI)和脑性瘫痪日常生活评价量表(ADL),比较治疗后药物对上述指标改善程度的差异。结果奥拉西坦可明显改善脑性瘫痪儿童智能和生活能力,实验组与对照组比较差异有显著性意义(P<0.05)。研究期间无药物相关不良反应发生,实验室检查没有明显改变。结论奥拉西坦可以改善脑性瘫痪的智能和生活能力,且具有很高的安全性。
Objective To study and evaluate the clinical effect and safety ofoxiracetam in the treatment of the children with cerebral palsy. Methods A randomized, double-blind, controlled study was carried out in 60 children with cerebral palsy. Of the 60 children, 30 as a control group were treated with positive drug piracetam and the others as an experimental group were treated with oxiracetam. The clinical indexes were evaluated with WPPSI （Wechsler Preschool and Primary Scale of Intelligence） and ADL （Activities of Daily Living） before and 4 weeks after therapy. Results The evaluation revealed that oxiracetam could induce a significant progxess of intelligence and living activities （P〈0.05 vs control group）. During the study, no drug-related side-effects were seen and laboratory examinations showed nothing abnormal. Conclusion Oxiracetam can improve effectively and with a high safety, the intelligence and living activities of the children with cerebral palsy.
出处
《中华神经医学杂志》
CAS
CSCD
2007年第4期409-411,共3页
Chinese Journal of Neuromedicine
关键词
奥托西坦
吡拉西坦
儿童脑性瘫痪
智能
生活能力
Oxiracetam
Piracetam
Cerebral palsy, children
Intelligence
Activities of living
